Calcipotriene ointment improved a child's skin condition known as En coup de sabre.
8 citations
,
January 2016 Curcumin can safely replace Sunset Yellow as a food colorant.
8 citations
,
August 2020 in “Domestic Animal Endocrinology” Melatonin improved cashmere production in goats during the first cycle but had no lasting effects on the next cycle.
88 citations
,
July 1958 in “Nature” Citrulline was found in hair follicle proteins for the first time.
January 2026 in “Journal of Innovative and Creativity (Joecy)” The 4% and 9% celery hair tonics are stable and suitable for herbal cosmetics.
7 citations
,
April 2006 in “Experimental Neurology” Finasteride blocks deoxycorticosterone's anticonvulsant effects in infant rats, but indomethacin doesn't.
26 citations
,
July 2007 in “Biochemical Pharmacology” ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” 17 citations
,
January 2015 in “JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH” Cronkhite-Canada syndrome is a rare, non-inherited condition causing various symptoms like polyps, hair loss, and weight loss.
December 2024 in “Chemical Senses” Taste disorders in Cronkhite-Canada syndrome are severe in the front of the tongue but improve with treatment.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
26 citations
,
July 1995 in “Small ruminant research” Melatonin implants affect the growth and pattern of cashmere goat fleece depending on the time of year they are given.
18 citations
,
February 2025 in “Drug Delivery and Translational Research” The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.
August 2023 in “Journal of Chromatographic Science” A new method accurately measures three compounds in rat plasma from pine needle extracts, aiding future research on its use for hair loss.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
1 citations
,
July 2017 in “PubMed” Two patients with Cronkhite-Canada syndrome achieved remission after treatment.
22 citations
,
January 1992 in “PubMed” Higher CSF 5-HIAA levels may predict better response to serotonin re-uptake inhibitors in trichotillomania.
5 citations
,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
2 citations
,
January 2023 in “Frontiers in Genetics” Overexpressing ovine β-catenin in mice skin increases hair follicle density and growth.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
5 citations
,
September 2013